Compare UiPath Inc (PATH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Recursion Pharmaceuticals Inc — how do they compare? UiPath Inc trades at $13.3 (market cap $6.81B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: UiPath Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 22,766,109). Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PATH | RXRX | |
|---|---|---|
Market Cap | $6.81B | $2.31B |
Volume | 22,766,109 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $19.29 | $6.79 |
52-Week Low | $9.38 | $2.84 |
Typical Hold Time | 139 Days | 22 Days |
Enterprise Value | $5.61B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
